Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01478269

Acronym

ProDLBCL

Enrollment

1927

Registered

2011-11-23

Start date

2009-05-31

Completion date

2011-05-31

Last updated

2011-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-Cell Lymphomas

Keywords

Aggressive B-cell lymphoma, R-CHOP

Brief summary

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007. 2. Any stage of disease. 3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant). 4. Age at least 18 years. 5. Availability of tissue biopsy at diagnosis for a possible centralized revision. 6. Availability of data on clinical involvement, laboratory, treatment and follow up.

Exclusion criteria

* None

Countries

Brazil, Italy

Outcome results